Short Interest in Evotec SE (NASDAQ:EVO) Increases By 23.5%

Evotec SE (NASDAQ:EVO) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 195,500 shares, an increase of 23.5% from the May 31st total of 158,300 shares. Based on an average daily trading volume, of 146,100 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several equities analysts have commented on EVO shares. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Evotec in a research report on Thursday, May 23rd. Deutsche Bank Aktiengesellschaft upgraded Evotec from a “hold” rating to a “buy” rating in a research report on Friday, April 12th.

Evotec Trading Up 1.9 %

NASDAQ:EVO traded up $0.09 on Tuesday, hitting $4.95. The stock had a trading volume of 31,345 shares, compared to its average volume of 114,430. The business’s fifty day moving average is $4.91 and its 200 day moving average is $7.07. The company has a quick ratio of 1.79, a current ratio of 1.86 and a debt-to-equity ratio of 0.43. Evotec has a 52 week low of $3.94 and a 52 week high of $13.49.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mubadala Investment Co PJSC bought a new position in shares of Evotec in the fourth quarter valued at approximately $53,931,000. Optiver Holding B.V. lifted its holdings in shares of Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares in the last quarter. Cetera Advisors LLC bought a new position in shares of Evotec in the first quarter valued at approximately $188,000. Finally, Quadrant Capital Group LLC bought a new position in shares of Evotec in the fourth quarter valued at approximately $25,000. Institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.